Cargando…
Insulin: a wonder drug in the critically ill?
Stress hyperglycaemia is a common event in acute critical illness. There is increasing evidence that maintaining normoglycaemia and treatment with insulin (or with glucose–insulin–potassium [GIK]), even in non-diabetic persons, is helpful in limiting organ damage after myocardial infarction, stroke,...
Autores principales: | , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC137286/ https://www.ncbi.nlm.nih.gov/pubmed/11983030 http://dx.doi.org/10.1186/cc1463 |
_version_ | 1782120423019773952 |
---|---|
author | Johan Groeneveld, AB Beishuizen, Albertus Visser, Frans C |
author_facet | Johan Groeneveld, AB Beishuizen, Albertus Visser, Frans C |
author_sort | Johan Groeneveld, AB |
collection | PubMed |
description | Stress hyperglycaemia is a common event in acute critical illness. There is increasing evidence that maintaining normoglycaemia and treatment with insulin (or with glucose–insulin–potassium [GIK]), even in non-diabetic persons, is helpful in limiting organ damage after myocardial infarction, stroke, traumatic brain injury and other conditions, even though the conditions may be accompanied by insulin resistance. A landmark study now suggests that maintaining normoglycaemia with intensive insulin treatment in a heterogeneous population of critically ill patients decreases morbidity and mortality. The potential mechanisms that underlie such a beneficial effect are discussed. |
format | Text |
id | pubmed-137286 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2002 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-1372862003-02-27 Insulin: a wonder drug in the critically ill? Johan Groeneveld, AB Beishuizen, Albertus Visser, Frans C Crit Care Commentary Stress hyperglycaemia is a common event in acute critical illness. There is increasing evidence that maintaining normoglycaemia and treatment with insulin (or with glucose–insulin–potassium [GIK]), even in non-diabetic persons, is helpful in limiting organ damage after myocardial infarction, stroke, traumatic brain injury and other conditions, even though the conditions may be accompanied by insulin resistance. A landmark study now suggests that maintaining normoglycaemia with intensive insulin treatment in a heterogeneous population of critically ill patients decreases morbidity and mortality. The potential mechanisms that underlie such a beneficial effect are discussed. BioMed Central 2002 2002-02-08 /pmc/articles/PMC137286/ /pubmed/11983030 http://dx.doi.org/10.1186/cc1463 Text en Copyright © 2002 BioMed Central Ltd |
spellingShingle | Commentary Johan Groeneveld, AB Beishuizen, Albertus Visser, Frans C Insulin: a wonder drug in the critically ill? |
title | Insulin: a wonder drug in the critically ill? |
title_full | Insulin: a wonder drug in the critically ill? |
title_fullStr | Insulin: a wonder drug in the critically ill? |
title_full_unstemmed | Insulin: a wonder drug in the critically ill? |
title_short | Insulin: a wonder drug in the critically ill? |
title_sort | insulin: a wonder drug in the critically ill? |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC137286/ https://www.ncbi.nlm.nih.gov/pubmed/11983030 http://dx.doi.org/10.1186/cc1463 |
work_keys_str_mv | AT johangroeneveldab insulinawonderdruginthecriticallyill AT beishuizenalbertus insulinawonderdruginthecriticallyill AT visserfransc insulinawonderdruginthecriticallyill |